

Letter to the Editor

J Vet Intern Med 2010;24:6
10.1111/j.1939-1676.2009.0433.x

Dear Editor

I would like to convey my disappointment for the numerous mistakes in the following paper: Masitinib is safe and effective for the treatment of canine mast cell tumors. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O. *J Vet Intern Med* 2008 November–December;22(6):1301–9. Epub September 24, 2008. Erratum in: *J Vet Intern Med* 2009 January–February;23(1):224. Ogilvie, G [corrected to Ogilvie, G].

Aside from the error in the name of one of the co-authors (acknowledged in the erratum), there are many other mistakes. In particular, almost all of the section on KIT detection status is identical with the same paragraph of another paper: Gain-of-function mutations in the

extracellular domain of KIT are common in canine mast cell tumors. Letard S, Yang Y, Hanssens K, Palmérini F, Leventhal PS, Guéry S, Moussy A, Kinet JP, Hermine O, Dubreuil P. *Mol Cancer Res* 2008 July;6(7):1137–45.

Table 3 in Hahn et al (2008) is misleading and refers to Table 3 of Letard et al (2008). Also, Figure 1, which is fundamental for understanding the entire paper, is completely mistaken.

I hope that a further Erratum will be published early. Thank you for your attention.

F. Gentilini
*Dipartimento Clinico Veterinario
Università di Bologna
Ozzano dell'Emilia
Bologna, Italy*